FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints metClinically meaningful microbiome ...

Vasoplegia is defined as sustained low systemic vascular resistance in the context of a normal or high cardiac index, leading ...

But you cannot fail early if you cannot see risk clearly. Drug development still relies heavily on sequential experimentation ...

Neurocrine Biosciences is in advanced talks to acquire Soleno Therapeutics for just over $2.5 billion, or low-to-mid $50s per ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...

Immune checkpoint inhibitors have reshaped cancer treatment over the past decade, but the same immune activation that shrinks tumors can also turn against healthy tissue, including the brain. A ...

Detailed price information for Artelo Biosciences Inc (ARTL-Q) from The Globe and Mail including charting and trades.

This manuscript reports an important study in which the authors apply smFRET imaging to probe HIV-1 Env conformational dynamics in the presence of antibodies. Previous implementations of smFRET ...

The Food and Drug Administration approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly. The high-dose ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg.

The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...